Taken together, PD-1+CD8+ TILs more accurately represent the tumour-specific subset than PD-1−CD8+ TIL counterpart, and hold greater potential for immunotherapy, even for HNSCC with primary resistance to α-PD-1 therapy. The gene discussed is CD8A; the disease is neoplasm.